Osiris Therapeutics (OSIR)
Osiris Therapeutics Revenue Growth: 2973%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
OSIR Revenue Growth Rankings
| Overall | 99th percentile | 8 of 4363 |
| Sector | 98th percentile | 6 of 457 in Healthcare |
| Industry | 95th percentile | 6 of 126 in Biotechnology |
OSIR Revenue Growth Range, Past 5 Years
| Minimum | 234.3% | Sep 2011 |
| Maximum | 2973% | Mar 2012 |
| Average | 1339% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these OSIR related companies
OSIR News
Unusual 11 Mid-Day Movers 05/31: (TLB) (CFK) (NEBS) Higher; (CHTP) (HMPR) (SMI) Lower
May 31, 1:07PM Street Insider
May 31, 1:07PM Street Insider
Morning Movers 05/31: (TLB) (CFK) (NEBS) (BONT) Higher; (CHTP) (AONE) (NCIT) (NBG) Lower
May 31, 11:09AM Street Insider
May 31, 11:09AM Street Insider
Vishay Intertechnology, The Fresh Market Included in Stocks Up on High Volume Wednesday
May 30, 12:33PM Fox Business
May 30, 12:33PM Fox Business
Morning Movers 05/30: (BAH) (TFM) (DGIT) Higher; (PBY) (TEA) (SURG) (PWRD) (MAGS) Lower
May 30, 11:20AM Street Insider
May 30, 11:20AM Street Insider
$OSIR spike on news of pass-through status for Grafix under Medicare's outpatient prospective payment system. http://stks.co/41yA
about a day ago by abubnic
about a day ago by abubnic
Pre-Open Movers 5/30: (NEON) (OSIR) (MON) Higher; (PBY) (PWRD) (RIMM) Lower (more...)
May 30, 9:37AM Street Insider
May 30, 9:37AM Street Insider
Osiris Therapeutics (OSIR) Wins Medicare Reimbursement Codes for Grafix
May 29, 5:13PM Street Insider
May 29, 5:13PM Street Insider
Large Pharmaceuticals Look to Biotech Industry to Provide New Streams of Revenue
May 23, 8:20AM Marketwire
May 23, 8:20AM Marketwire
@epime7heus $OSIR moved up fast. Broke over trigger @ 6.45 and hit 6.55 (tweet point) fast. 1st possible support point was 6.45, 2nd 6.36
about 9 days ago by StockHorizon
about 9 days ago by StockHorizon
6 breakouts: $OSIR (stop: $5.69). Two sub-$1 stocks. For a rally off a bottom it was a little disappointing not to see more here.
about 10 days ago by fallondpicks
about 10 days ago by fallondpicks
Osiris Therapeutics (OSIR) Volatility Up as Shares Move to 10-Month High
May 21, 1:40PM Street Insider
May 21, 1:40PM Street Insider
Salesforce.com, Winnebago Industries Included in Stocks Up on High Volume Friday
May 18, 12:32PM Fox Business
May 18, 12:32PM Fox Business
Osiris (OSIR) Wins Marketing Clearance for Prochymal from Health Canada
May 17, 4:47PM Street Insider
May 17, 4:47PM Street Insider
Listen to $OSIR Q1 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3mkR
about 20 days ago by earningscast
about 20 days ago by earningscast
Trading Radar for 05/11: Gordmans (GMAN), Dr. Reddys (RDY), Cache (CACH), Osiris Therapeutics (OSIR) Report
May 10, 5:52PM Street Insider
May 10, 5:52PM Street Insider
Osiris Therapeutics Announces First Quarter 2012 Financial Results Conference Call
May 03, 5:00PM Business Wire
May 03, 5:00PM Business Wire
Avoid Osiris Therapeutics $OSIR $QQQ $IWM $$ #biotech #KSMT http://stks.co/2rhR via @jnapodano
about 78 days ago by MichaelKudrna
about 78 days ago by MichaelKudrna
Listen to $OSIR Q4 2011 earnings call - live at 09:00 AM, ondemand after - http://stks.co/2l3X
about 83 days ago by earningscast
about 83 days ago by earningscast
$OSIR will report its financial results for Q4 and full year on Friday, March 9. Webcast @ 9am. http://stks.co/2f07
about 89 days ago by abubnic
about 89 days ago by abubnic
Here's explanation we waited for yesterday: $OSIR Provides Update On Sanofi Deal. http://stks.co/2MBd
about 111 days ago by abubnic
about 111 days ago by abubnic
No word from $OSIR CEO on whether Sanofi action is
a cost-saving initiative or if they have plans to
dissolve other Osiris/Sanofi programs.
about 112 days ago by abubnic
about 112 days ago by abubnic
$OSIR drops after Sanofi discontinues P3 GvHD Program. http://stks.co/2KlB
about 112 days ago by abubnic
about 112 days ago by abubnic
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| OSIR | 6.31 | -0.67 | -9.60% | 229.15M |
| OSHC | 11.98 | -0.02 | -0.17% | 87.48M |
| OSG | 10.93 | -0.08 | -0.73% | 335.25M |
| OSBC | 1.33 | +0.07 | +5.56% | 17.74M |
| ORRF | 7.55 | +0.03 | +0.40% | 60.61M |
| ORLY | 95.95 | +0.23 | +0.24% | 12.16B |
| ORI | 9.88 | +0.00 | +0.00% | 2.562B |
| OREX | 3.345 | -0.07 | -2.19% | 231.67M |
| SWX | 41.97 | +0.23 | +0.55% | 1.924B |
| SWU | 117.64 | +0.51 | +0.44% |
